The European Society for Medical Oncology (ESMO) released today the ESMO Guidance on the Use of Large Language Models in ...

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

Circulating tumor DNA (ctDNA) — genetic material shed from tumors into the bloodstream — may help risk-stratify patients with ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant ...

Penn State Health held a bell-ringing ceremony on Monday, Oct. 20, for a new cancer center that will open in Enola. The Penn ...

Zanzalintinib and atezolizumab improved overall survival in metastatic colorectal cancer compared to regorafenib, with a median OS of 10.9 vs 9.4 months. The combination showed progression-free ...

Investing.com -- Kura Oncology Inc (NASDAQ:KURA) stock rose 4.7% in Monday premarket trading following the company’s presentation of encouraging clinical data for its farnesyl transferase inhibitor ...

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

The state-of-the-workforce report identifies challenges in cancer care access across the US, particularly in rural areas.